Plain-language summary

This Phase 2 trial is testing Mogamulizumab, Total Skin Electron Beam Therapy (TSEB), and other medications for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join (key eligibility)

• Age 18 Years or older
• Lymphoma came back or did not respond to prior treatment
• Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Mogamulizumab (DRUG): • Patients will receive mogamulizumab 1.0 mg/kg IV over at least 1 hour on Days 1, 8, 15 and 22 of the first 28 day treatment cycle (C1) and on Days 1 and 15 of subsequent 28 day cycle (C2). | Total Skin Electron Beam Therapy (TSEB) (RADIATION): * After completion of C2, patients will be administered TSEB at a dose of 12 Gy in 8 fractions (4 fractions per week). TSEB will start 28 days (window of + 7 days) after mogamulizumab (C2 D1). * In case of toxicity from mogamulizumab, the maximum delay permitted for the start of TSEB is 2 weeks. * If recovery to at least grade 1 from toxicity exceeds the 2 weeks interval, please contact the medical monitor. * Mogamulizumab is stopped during TSEB administration. | Mogamulizumab (subsequent cycles post TSEB) (DRUG): • Mogamulizumab will be restarted at a dose of 1.0 mg/kg IV on Days 1, 8, 15 and 22 for cycle 3. Subsequent cycles will be administered as for C2. Treatment with mogamulizumab will be continued until disease progression (PD) or the occurrence of another withdrawal criterion.

Drugs / treatments

Mogamulizumab, Total Skin Electron Beam Therapy (TSEB), Mogamulizumab (subsequent cycles post TSEB)

Treatment length

Ask the trial team for details

Visit frequency

Ask the trial team for details